Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Yu KD" with an ORCID

Ke-Da Yu
No affiliation detected
3
Publications
28
Citations
View profile

Search results

1-25 of 168 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.
Cai Y, Liu CC, Zhang Y, Liu Y, Chen L, Xiong X, Shao Z, Yu KD
J Clin Invest, e183656, 12 Nov 2024
Cited by: 0 articles | PMID: 39531335
Add to export list
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, [...] Shao ZM
BMJ, 387:e079603, 23 Oct 2024
Cited by: 0 articles | PMID: 39442958 | PMCID: PMC11497771
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era.
Xiong X, Wang X, Liu CC, Shao ZM, Yu KD
Biomark Res, 12(1):107, 18 Sep 2024
Cited by: 0 articles | PMID: 39294728 | PMCID: PMC11411917
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.
Zuo WJ, Chen L, Shen Y, Wang ZH, Liu GY, Yu KD, Di GH, Wu J, Li JJ, Shao ZM
Ther Adv Med Oncol, 16:17588359231225032, 14 Feb 2024
Cited by: 1 article | PMID: 38362377 | PMCID: PMC10868472
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.
Liu CC, Chen L, Cai YW, Chen YF, Liu YM, Zhou YJ, Shao ZM, Yu KD
Cell Rep Med, 5(2):101396, 29 Jan 2024
Cited by: 0 articles | PMID: 38290515 | PMCID: PMC10897545
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, [...] Shao ZM
Lancet Oncol, 25(2):184-197, 08 Jan 2024
Cited by: 10 articles | PMID: 38211606
Add to export list
Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program.
Yu KD, Betts MN, Urban GM, Schwartz MLB, Robinson TO, Moyer RJ, Taddonio SW, Vasudevan A, Johns A, Sturm AC, Kelly MA, Williams MS, Poler SM, Buchanan AH
Anesthesiology, 140(1):52-61, 01 Jan 2024
Cited by: 1 article | PMID: 37787745
Add to export list
Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer.
Zheng LW, Liu CC, Yu KD
J Hematol Oncol, 16(1):123, 18 Dec 2023
Cited by: 8 articles | PMID: 38110976 | PMCID: PMC10726551
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.
Chen L, Liu CC, Zhu SY, Ge JY, Chen YF, Ma D, Shao ZM, Yu KD
JCI Insight, 8(22):e172366, 22 Nov 2023
Cited by: 2 articles | PMID: 37991016 | PMCID: PMC10721318
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet, 402(10416):1991-2003, 03 Nov 2023
Cited by: 18 articles | PMID: 37931633
Add to export list
Inconsistent Data Between Distant Relapse Events and Breast Cancer-Specific Death Events in India Lidocaine Trial.
Yu KD
J Clin Oncol, 41(29):4707-4708, 11 Jul 2023
Cited by: 0 articles | PMID: 37433105
Add to export list
Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening.
Gidding SS, Kirchner HL, Brangan A, Howard W, Kelly MA, Myers KD, Morgan KM, Oetjens MT, Shuey TC, Staszak D, Strande NT, Walters NL, Yu KD, Wilemon KA, Williams MS, Sturm AC, Jones LK
J Am Heart Assoc, 12(13):e030073, 29 Jun 2023
Cited by: 2 articles | PMID: 37382153 | PMCID: PMC10356068
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: [email protected], Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Lancet, 401(10384):1277-1292, 01 Apr 2023
Cited by: 28 articles | PMID: 37061269
Add to export list
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ, Wang ZH, Shao ZM
Cell Res, 33(5):389-402, 27 Mar 2023
Cited by: 19 articles | PMID: 36973538 | PMCID: PMC10156707
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Neoadjuvant Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trial.
Gong Y, Zuo H, Zhou Y, Yu KD, Liu GY, Di GH, Wu J, Liu ZB, Shao ZM
Ann Transl Med, 11(6):243, 13 Feb 2023
Cited by: 3 articles | PMID: 37082658 | PMCID: PMC10113104
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
[Network Meta-analysis of single Hirudo prescriptions in treatment of ischemic cerebrovascular disease].
Yan ZF, Sun RH, Chen YF, Yu KD
Zhongguo Zhong Yao Za Zhi, 48(4):1108-1115, 01 Feb 2023
Cited by: 1 article | PMID: 36872281
Add to export list
Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination.
Liu YM, Ge JY, Chen YF, Liu T, Chen L, Liu CC, Ma D, Chen YY, Cai YW, Xu YY, Shao ZM, Yu KD
Adv Sci (Weinh), 10(6):e2205395, 03 Jan 2023
Cited by: 21 articles | PMID: 36594618 | PMCID: PMC9951304
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Facilitation of non-indigenous ascidian by marine eco-engineering interventions at an urban site.
Schaefer N, Sedano F, Bishop MJ, Dunn K, Haeusler MH, Yu KD, Zavoleas Y, Dafforn KA
Biofouling, 39(1):80-93, 01 Jan 2023
Cited by: 1 article | PMID: 36912169
Add to export list
Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.
Chen YF, Xu YY, Shao ZM, Yu KD
Cancer Commun (Lond), 43(3):297-337, 10 Nov 2022
Cited by: 24 articles | PMID: 36357174 | PMCID: PMC10009672
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Investigating Psychological Impact after Receiving Genetic Risk Results-A Survey of Participants in a Population Genomic Screening Program.
McCormick CZ, Yu KD, Johns A, Campbell-Salome G, Hallquist MLG, Sturm AC, Buchanan AH
J Pers Med, 12(12):1943, 22 Nov 2022
Cited by: 3 articles | PMID: 36556164 | PMCID: PMC9781266
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Dexmedetomidine Promotes Angiogenesis and Vasculogenic Mimicry in Human Hepatocellular Carcinoma through α ₂-AR/HIF-1α/VEGFA Pathway.
Fang T, Lin L, Ye ZJ, Fang L, Shi S, Yu KD, Miao HH, Li TZ
Biomed Environ Sci, 35(10):931-942, 01 Oct 2022
Cited by: 3 articles | PMID: 36443270
Add to export list
Towards a low carbon ASEAN: an environmentally extended MRIO optimization model.
Amheka A, Nguyen HT, Yu KD, Noach RM, Andiappan V, Dacanay VJ, Aviso K
Carbon Balance Manag, 17(1):13, 07 Sep 2022
Cited by: 0 articles | PMID: 36070153 | PMCID: PMC9454141
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, [...] Shao ZM
Clin Cancer Res, 28(13):2807-2817, 01 Jul 2022
Cited by: 35 articles | PMID: 35247906 | PMCID: PMC9365373
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?
Qu FL, Lin CJ, Liu ZB, Cao AY, Wu J, Liu GY, Yu KD, Di GH, Li JJ, Shao ZM
Breast Cancer Res Treat, 196(1):97-109, 30 Aug 2022
Cited by: 0 articles | PMID: 36040640 | PMCID: PMC9550716
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis.
Cai YW, Shao ZM, Yu KD
Front Immunol, 13:919369, 30 Jun 2022
Cited by: 3 articles | PMID: 35844533 | PMCID: PMC9279606
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 168 results

1 2 3 Next ...

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Yu KD" with an ORCID

Search results

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer.

Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.

Deciphering breast cancer dynamics: insights from single-cell and spatial profiling in the multi-omics era.

Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.

Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer.

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.

Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program.

Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer.

Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.

Inconsistent Data Between Distant Relapse Events and Breast Cancer-Specific Death Events in India Lidocaine Trial.

Yield of Familial Hypercholesterolemia Genetic and Phenotypic Diagnoses After Electronic Health Record and Genomic Data Screening.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.

Neoadjuvant Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) and chemotherapy versus placebo plus chemotherapy in patients with HER2-negative breast cancer: a randomized, controlled, double-blind trial.

[Network Meta-analysis of single Hirudo prescriptions in treatment of ischemic cerebrovascular disease].

Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination.

Facilitation of non-indigenous ascidian by marine eco-engineering interventions at an urban site.

Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.

Investigating Psychological Impact after Receiving Genetic Risk Results-A Survey of Participants in a Population Genomic Screening Program.

Dexmedetomidine Promotes Angiogenesis and Vasculogenic Mimicry in Human Hepatocellular Carcinoma through α ₂-AR/HIF-1α/VEGFA Pathway.

Towards a low carbon ASEAN: an environmentally extended MRIO optimization model.

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.

Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?

Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis.

Partnerships & funding

Search life-sciences literature (45,100,050 articles, preprints and more)

Suggested authors matching "AUTH:Yu KD" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Yu KD" with an ORCID